> ## Content Index
> Fetch the complete content index at: https://nephspace.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Deep Dive · Two Roads: Hemodiafiltration or Medium Cutoff Dialyzers?
- URL: https://nephspace.com/two-roads/
- Published: 2026-10-02T00:34:00.000Z
- Updated: 2026-10-04T19:23:26.000Z
- Description: Two dialysis patients, same city, same week. One gets a new machine that filters and replaces more than 20 liters every session. The other gets the same old machine with a new filter. Both are told it's the future. Hemodiafiltration has a survival trial but needs new machines. Medium cutoff…
- Author: Dr Wael Hussein
- Tags: Episodes, Dialysis, #deep-dive, #has-audio, #tr-5b3a2d4e

Two dialysis patients, same city, same week. One gets a new machine that filters and replaces more than 20 liters every session. The other gets the same old machine with a new filter. Both are told it's the future. Hemodiafiltration has a survival trial but needs new machines. Medium cutoff dialyzers drop into today's machines but have no survival evidence against standard dialysis. A detective story with a Fight Night verdict, including who makes, sells and funds each road.

**The takeaway:** Both roads clear more middle molecules, but only hemodiafiltration has shown that people live longer, and only in patients who can get the dose.

**Disclosure:** Dr. Hussein serves on the Fresenius Medical Care US Home Medical Advisory Board. Fresenius makes and sells the 5008X hemodiafiltration machine discussed in this episode. The episode names the industry ties of the review authors and of everyone quoted.

## Chapters

- **00:00** Cold open and disclosure.
- **01:11** The mystery: what middle molecules are, and why clearing them might matter.
- **02:47** Road one, change the treatment: CONVINCE, its quality-of-life and cost papers, and the JASN review. [Read the story](https://nephspace.com/hdf-review-jasn/)
- **08:36** Road two, change the filter: Theranova, ELISIO-HX and the medium cutoff evidence. [Read the story](https://nephspace.com/mco-dialyzers-davita-qa/)
- **11:47** The showdown: MOTheR, the head-to-head trial.
- **15:13** Follow the money: who makes, sells and funds each road.
- **16:49** Fight Night verdict and the Monday-morning change.

## Papers discussed

- Blankestijn PJ, et al. Hemodiafiltration: Clinical Practice of Today and a Look into the Future. JASN 2026 (ahead of print). [Link](https://doi.org/10.1681/ASN.0000001282?ref=nephspace.com)
- Healio | Nephrology, September 24, 2026\. Q&A with DaVita's chief medical officer on medium cutoff dialyzers. [Link](https://www.healio.com/news/nephrology/20260924/qa-recent-fda-approval-prompts-expansion-of-medium-cutoff-dialyzers?ref=nephspace.com)
- Blankestijn PJ, et al. Effect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure (CONVINCE). N Engl J Med 2023;389:700-709\. [Link](https://doi.org/10.1056/NEJMoa2304820?ref=nephspace.com)
- Rose M, et al. CONVINCE quality-of-life results. Kidney Int 2024;106:961-971\. [Link](https://doi.org/10.1016/j.kint.2024.07.014?ref=nephspace.com)
- Schouten AEM, et al. CONVINCE cost-utility analysis. Kidney Int 2025;107:728-739\. [Link](https://doi.org/10.1016/j.kint.2024.12.018?ref=nephspace.com)
- Vernooij RWM, et al. Haemodiafiltration versus haemodialysis for kidney failure: an individual patient data meta-analysis of randomised controlled trials. Lancet 2024;404:1742-1749 (abstract only). [Link](https://doi.org/10.1016/S0140-6736%2824%2901859-2?ref=nephspace.com)
- Kandi M, et al. Clinical Outcomes With Medium Cut-Off Versus High-Flux Hemodialysis Membranes: A Systematic Review and Meta-Analysis. Can J Kidney Health Dis 2022;9\. [Link](https://doi.org/10.1177/20543581211067087?ref=nephspace.com)
- MOTheR trial (Theranova expanded hemodialysis vs online hemodiafiltration), presented at the ERA Congress, June 2026, not yet peer-reviewed. Healio, June 18, 2026\. [Link](https://www.healio.com/news/nephrology/20260618/expanded-hemodialysis-noninferior-to-online-hemodiafiltration?ref=nephspace.com)
- National Kidney Foundation. Medium Cut-Off Dialyzers for Expanded Hemodialysis: A Clinical Update. [Link](https://www.kidney.org/professionals/medium-cut-dialyzers-expanded-hemodialysis?ref=nephspace.com)

### Company and provider statements cited (promotional sources, labeled as such on air)

- Vantive, June 8, 2026 (MOTheR and CONCORDIA). [Link](https://www.globenewswire.com/news-release/2026/06/08/3308370/0/en/vantive-highlights-late-breaking-high-clinical-impact-data-at-era-indicating-hdx-therapy-is-a-practical-alternative-to-online-hemodiafiltration.html?ref=nephspace.com)
- Fresenius Medical Care, June 2026, "High-Volume Hemodiafiltration Remains the Benchmark for Survival Evidence in Dialysis". [Link](https://freseniusmedicalcare.com/en/media/insights/blog/high-volume-hemodiafiltration-remains-the-benchmark-for-survival/?ref=nephspace.com)
- DaVita newsroom, August 5, 2026\. [Link](https://newsroom.davita.com/davita-scales-expanded-hd-to-target-middle-molecules/?ref=nephspace.com)
- U.S. Renal Care, July 30, 2026\. [Link](https://www.prnewswire.com/news-releases/us-renal-care-drives-innovation-in-dialysis-with-increased-availability-of-medium-cut-off-dialyzers-to-support-expanded-hemodialysis-302839595.html?ref=nephspace.com)
- Healio perspective, February 24, 2026, "Middle molecule moment" (Chan and Sonti). [Link](https://www.healio.com/news/nephrology/20260224/middle-molecule-moment-hemodiafiltration-and-expanded-hemodialysis-transform-us-dialysis?ref=nephspace.com)

Also cited by name: Baxter's August 2020 Theranova authorization announcement, Nipro's July and August 2026 ELISIO-HX releases, and Fresenius's 2025 and 2026 releases on the 5008X rollout.

**Listen anywhere:** [Apple Podcasts](https://podcasts.apple.com/podcast/nephspace/id6818364609?ref=nephspace.com) · [Spotify](https://open.spotify.com/show/13ehzk9U414PYpIZK3c4yv?ref=nephspace.com) · [other apps](https://nephspace.com/tag/episodes/#other-apps). **Discuss:** [NephSpace on LinkedIn](https://www.linkedin.com/company/nephspace?ref=nephspace.com).

*Physician-led, AI-assisted. Dr. Wael Hussein chooses the papers, reviews and edits every script, and approves every episode. AI (Claude, by Anthropic) writes the first draft from the full text of each paper, and a separate AI check compares every number with the papers; Dr. Hussein then reviews and edits the draft before the AI hosts (ElevenLabs) voice it. Everything is summarized in our own words. For education and information only, not medical advice. Please talk to your own physician or care team about your health. Clinicians: read the original before changing practice. See our* [*disclaimer*](https://nephspace.com/disclaimer/)*. Views are the creator's own and not those of his employer. No sponsors.*